SKU: SKU: C3 B10-NMP22
ABBOTT MEDICAL GMBH NMP22 BladderCheck test
Verpackungseinheit : 10 tests
Couldn't load pickup availability
The Alere NMP22 BladderChek is a rapid, simple, and non-invasive test to support the detection and monitoring of bladder cancer. The test detects a nuclear matrix protein released by urothelial tumor cells, indicating the presence of bladder cancer. With a sensitivity of over 82% (up to 94% depending on the tumor stage) and a specificity of 76%, the test offers a reliable means of early diagnosis of bladder cancer. When combined with urine cytology, the sensitivity increases to nearly 100%.
Areas of application:
-
Early detection of bladder cancer: Particularly useful for identifying bladder cancer in high-risk patients.
-
Monitoring of high-risk patients: For patients with a history of bladder cancer or those who are in risk groups for bladder cancer
-
Diagnostic support: Helps with diagnosis in combination with conventional diagnostic procedures
-
Regular tests: Suitable for clinical and outpatient examinations for regular monitoring
Advantages at a glance:
-
Quick and easy: Results within 30 minutes, so they can be shared directly during the same doctor's visit.
-
Non-invasive: The test requires no invasive procedures and is easy to perform.
-
High sensitivity: Sensitivity of over 82%, which increases to almost 100% with urine cytology.
-
Cost-efficient: Fast, inexpensive and reliable
-
Supports diagnosis: Complements other diagnostic procedures and helps in the identification of bladder cancer.
Further information:
-
The test helps to quickly and effectively confirm or rule out suspected bladder cancer, especially in high-risk patients.
-
It is a non-invasive alternative to more invasive diagnostic procedures and can be used for regular check-ups.
Delivery information:
PZN:
WEEE number:
Assistive device number:
Manufacturer:
ABBOTT MEDICAL GMBH
Schanzenfeldstraße 2
D–35578 Wetzlar
Deutschland
Tel: +49 (0) 6441 870 75 0
Email: WETCustomerService@av.abbott.com
VAT ID number: